Results 111 to 120 of about 5,245,541 (298)
Rationally engineered polymeric interfaces for selective and dynamic recognition of vesicular agents
This review explores how molecularly imprinted polymers can be engineered to recognize complex nanoscale vesicles, including extracellular vesicles and membrane‐enveloped viruses. By tailoring polymer cavities to vesicle surface chemistry and structure, these synthetic receptors support selective detection, separation, and integration with optical ...
Özgecan Erdem +4 more
wiley +1 more source
Background There is a growing interest in products featuring hemp extracts and a demand for more data regarding their safety. To date, there is a paucity of published data on the safety of these products. Methods A retrospective analysis of postmarketing
Colleen M. Kingsbury +2 more
doaj +1 more source
Efficacy, retention, and safety of baricitinib in real-life: HUR-BIO monocentric experience
Objective: This study evaluates the effectiveness, retention rate and safety of baricitinib, including a comparison between baricitinib and a tumour necrosis factor inhibitor (adalimumab) in a real-life cohort of patients with rheumatoid arthritis (RA).
Mustafa Ekici +15 more
doaj +1 more source
This prospective study demonstrates that laparoscopic sphincter‐preserving surgery is feasible for elderly patients. While overall survival reaches 70% at 5 years, advanced T‐stage and the omission of neoadjuvant therapy significantly drive recurrence, highlighting the need for personalized geriatric protocols despite logistical challenges.
Huu Duc Ho +4 more
wiley +1 more source
Background Immune checkpoint inhibitors (ICIs) have transformed tumor treatment. However, the risk of pulmonary adverse events (PAEs) associated with ICI combination therapy is still unclear.
Baohui Hong +6 more
doaj +1 more source
Target-specific cardiotoxicity of tyrosine kinase inhibitors: a Systematic Review and meta-analysis
ObjectiveTo assess the association between different tyrosine kinase inhibitors (TKIs) and the risk of major adverse cardiovascular events (MACE).Data sourcesPubMed, the Cochrane Library, Embase, WanFang Data, and CNKI were searched for randomized ...
Zhe Wang +10 more
doaj +1 more source
Adverse drug events affecting medication persistence with rivastigmine patch application
Takashi Osada,1 Norio Watanabe,1 Naomitsu Asano,2 Yuzo Adachi,2 Keiko Yamamura1 1Clinical Pharmacy, School of Pharmacy, Aichi Gakuin University, Nagoya, Aichi, Japan; 2Sasayuri Pharmacy, Toki, Gifu, Japan Purpose: The rivastigmine transdermal patch ...
Osada T +4 more
core
Cancer treatment is associated with measurable acceleration of biological aging across epigenetic, telomere, senescence, and immune biomarkers. However, biomarker validation and interventional strategies remain limited, especially in hematologic malignancies, underscoring the need for standardized multi‐omic aging assessments and adequately powered ...
Moataz Ellithi +3 more
wiley +1 more source
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
Evaluation of Adverse Events during Plateletpheresis – A Retrospective Study
Introduction: Apheresis is a routine procedure which is well tolerated but may be associated with different adverse events (AEs). In this study, the frequency of various AEs associated with apheresis was evaluated, and the donor variables were analyzed ...
Shivali Sehgal +5 more
doaj +1 more source

